AIM
CBAY

Acrospire Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

Acrospire Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,876
Closed -$11K – 1556
2017
Q2 		$11K Sell
1,876
-7,793
-81% -$33.2K 0.01% 1779
2017
Q1 		$42K Sell
9,669
-831
-8% -$2.38K 0.03% 1106
2016
Q4 		$18K Buy
10,500
+7,900
+304% +$13.9K 0.01% 1796
2016
Q3 		$5K Sell
2,600
-300
-10% -$597 ﹤0.01% 1833
2016
Q2 		$5K Buy
+2,900
New +$6.01K ﹤0.01% 1869

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Acrospire Investment Management's CBAY Position: Q3 2017 in Review

Acrospire Investment Management sold out of Cymabay Therapeutics (CBAY) in Q3 2017, closing a stake of 1,876 shares — an estimated $11K sold.

Acrospire Investment Management first reported a position in CBAY in Q2 2016 and held it in 5 quarters. The position peaked at $42K in Q1 2017. 64 funds tracked by Wall St. Rank hold CBAY as of Q3 2017.

  • Acrospire Investment Management reported no remaining Cymabay Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,876 Cymabay Therapeutics shares in Q3 2017, an estimated $11K.
  • Acrospire Investment Management first reported a position in Cymabay Therapeutics in Q2 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Cymabay Therapeutics position peaked at $42K in Q1 2017.
  • 64 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.